Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists

US9775904B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Martin Bossart · Frankfurt am Main, DE
• Ralf Elvert · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Siegfried Stengelin · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE

Key dates

• Filing date: Apr 6, 2015
• Grant date: Oct 3, 2017
• Expiry date: Apr 6, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/46
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.